Last reviewed · How we verify
pegademase
pegademase is a drug. It is currently in unknown development for Adenosine deaminase deficiency.
At a glance
| Generic name | pegademase |
|---|---|
| Therapeutic area | Other |
| Phase | unknown |
Approved indications
- Adenosine deaminase deficiency
Common side effects
Key clinical trials
- Efficacy and Safety of Cryopreserved Formulation of Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for Human ADA (Phase 1)
- Efficacy and Safety of a Cryopreserved Formulation of Autologous CD34+ Haematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1α Short Form (EFS) Lentiviral Vector Encoding for Human ADA (Phase 1)
- A Retrospective and Cross-Sectional Analysis of Patients Treated for SCID Since January 1,1968 (RDCRN PIDTC-6902) (N/A)
- Autologous Transplantation of Bone Marrow CD34+ Stem/Progenitor Cells After Addition of a Normal Human ADA Complementary DNA (cDNA) by the EFS-ADA Lentiviral Vector for Severe Combined Immunodeficienc (Phase 1)
- Phase I/II, Historical Controlled, Open-label, Non-randomised, Single-centre Trial to Assess the Safety and Efficacy of EF1αS-ADA Lentiviral Vector Mediated Gene Modification of Autologous CD34+ Cells (Phase 1)
- A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children With SCID Disorders (RDCRN PIDTC-6901) (N/A)
- Single Arm, Open-Label, Multicenter, Registry Study of Revcovi (Elapegademase-lvlr) Treatment in ADA-SCID Patients Requiring Enzyme Replacement Therapy (N/A)
- MND-ADA Transduction of CD34+ Cells From the Bone Marrow Of Children With Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID): Effect of Discontinuation of PEG-ADA and Marrow C (Phase 2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pegademase CI brief — competitive landscape report
- pegademase updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about pegademase
What is pegademase?
pegademase is a pharmaceutical drug, indicated for Adenosine deaminase deficiency.
What is pegademase used for?
pegademase is indicated for Adenosine deaminase deficiency.
What development phase is pegademase in?
pegademase is in unknown.
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Adenosine deaminase deficiency
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing